AI-generated · cited to primary sources · not investment advice · How we research
Biocon
Our verdict on Biocon isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company confirmed the successful launch of bBevacizumab during the quarter. (1 met, 1 exceeded across 2 tracked commitments)
“Generics: Early investments in GLP-1s and peptide APIs are gaining traction; upcoming launches to fuel double-digit growth for the full year”
R&D spending for the Biosimilars segment was optimized to 6% of revenue for the full year, which is below the guided range of 7-9%, indicating better cost control. (1 exceeded, 4 met across 5 tracked commitments)
“We've said, Tushar, that we would be in that 7% to 9% of revenues for R&D, and we continue to be in that range even now and on a full year basis, you will see us in that 7% to 9% range.”
The extension of the BMS partnership through 2035 with expanded scope was confirmed in the FY26 performance update. (1 met across 1 tracked commitment)
“Continued focus on translating recent investments in capabilities to more stable performance at Syngene”
Management confirmed the successful launch of Jobevne (biosimilar Bevacizumab) within the last 9 months. (1 met across 1 tracked commitment)
“And in regard to Bevacizumab, you'll see this launching towards the end of the summer around the October time frame and which will continue to start leveraging our oncology portfolio and ramping up our payor strategies as we go into the first of the year.”
The company received U.S. FDA approvals for liraglutide during the quarter for both diabetes and weight management indications. (1 met across 1 tracked commitment)
“We definitely do expect the approval to come in sometime this fiscal. I cannot comment on the timing exactly, but we do expect a launch in the U.S. during this fiscal.”
See the full cited Management analysis of Biocon
How durable is the business?
Manufacturing scale is expanding with the commissioning of a new injectable facility for GLP-1s and the expansion of the Malaysia insulin facility to address global demand spikes. (2 expanding, 1 stable)
“Major capacity build-out across biosimilars, insulins, peptides and complex generics substantially complete”
EBITDA margins for the biosimilar segment expanded significantly due to operating leverage and economies of scale as the company transitions into its 'Accelerate' phase. (1 expanding, 1 shifted, 1 stable)
“One Unified Global Biopharma Platform... Integration of Biocon Biologics into Biocon successfully completed... Major capacity build-out across biosimilars, insulins, peptides and complex generics substantially complete”
The segment (Syngene) has been renamed to CRDMO to reflect its evolving profile. It showed healthy growth of 11% YoY, driven by pilot programs transitioning into long-term contracts. (2 expanding, 2 contracting, 1 stable across 1 engine)
“Segment Revenue 1,037 ... EBITDA 326 ... % of Revenue 31%”
While revenue grew 6% YoY, the segment's EBITDA margin collapsed to near zero (0.1%) due to ramp-up costs for new facilities and heavy R&D investment in GLP-1 products. (1 contracting, 1 shifted)
“EBITDA 1 [Q1 FY26] ... 59 [Q1 FY25] ... EBITDA for the quarter reflects ramp-up costs associated with operationalizing new facilities”
Revenue growth slowed to 6% YoY as the previous quarter's spike from Lenalidomide was a one-time event. Margins are under temporary pressure (INR 60 Cr/quarter) due to the costs of operationalizing three new facilities. (2 contracting)
“Generics grew 6% year-on-year... The impact of all these facilities operating costs is in the P&L... roughly INR 60 crores a quarter.”
See the full cited Business Model analysis of Biocon
Where does growth come from?
The total insulin franchise has become a major pillar for the company, now generating over $300 million in annual revenue.
“Insulin now has crossed $300 million this year. So that's the bracket that it has crossed and that includes Glargine, Aspart, human insulin, DS and DP.”
Capital expenditure is decelerating as major projects reach completion, shifting the company from a heavy investment phase to a cash-generation phase. (1 decelerating, 3 steady, 1 new trend across 5 signals, 2 leading indicators)
“Biosimilars revenue for Q4 FY '26 stood at ₹2,756 crores, representing a 12% year-on-year increase, driven primarily by advanced markets.”
The CRDMO segment (Contract Research, Development, and Manufacturing) grew 11% YoY. Growth is being driven by pilot programs (small-scale tests) successfully turning into long-term, stable contracts. (3 steady, 1 new trend across 4 signals)
“BMS partnership extended through to 2035, expanded scope across discovery, development, manufacturing and clinical services”
Biocon continues to invest heavily in the future, with R&D spending at 10% of revenue for the Generics segment, specifically targeting the high-growth GLP-1 (weight loss) market. (1 steady across 1 signal)
“R&D investments at 10% of revenue, primarily focused on GLP-1 portfolio advancement.”
The company has transitioned from construction to commissioning, with the new injectables facility for GLP-1s now commissioned and commercial supply expected to begin in FY27. (4 steady, 1 new trend across 5 signals)
“Our injectables facility primarily focused on GLP-1s has been commissioned with commercial supply expected to begin in FY '27.”
See the full cited Future Growth analysis of Biocon
What could break the thesis?
The risk is easing due to successful regulatory approvals and launches of key products like Kirsty (Insulin Aspart) and Yesafili (Aflibercept). (2 easing, 1 stable)
“Received US FDA approval for Kirsty™ (bInsulin Aspart)... Launched Yesafili™, the first biosimilar Aflibercept launch in Canada”
Management believes they are well-positioned against Chinese competitors due to vertical integration and competitive manufacturing costs, particularly for recombinant APIs required for oral formulations. (1 stable)
“We know what the Chinese companies, who are supplying to a few other generic companies, what cost what selling price they're supplying the drug substance, and we know our own costs. So we think we are very well placed compared to our competitors”
Management notes that Biocon remains the only biosimilar insulin player in the U.S. and Europe at this point, suggesting the immediate threat from new entrants is lower than previously feared. (1 easing, 2 stable)
“We have not seen any other biosimilar insulin really in the U.S. at this point in time or in Europe... there is really no biosimilar player other than us at this point.”
A specific regulatory hurdle has emerged in Canada regarding GLP-1 (Liraglutide) approvals, where the regulator has not yet approved any generic files due to evolving requirements for preclinical work. (1 intensifying)
“The review cycle is long drawn, especially in markets such as Canada, where we have not seen a single generic GLP being approved, including liraglutide.”
The risk is intensifying as Generics EBITDA plummeted to 0% margin in Q1 FY26 from 9% in the previous year, driven by ramp-up costs of new facilities. (1 intensifying, 4 easing)
“EBITDA for the quarter reflects ramp-up costs associated with operationalizing new facilities... EBITDA % of Total Revenue 0%”
See the full cited Risk analysis of Biocon
Biocon analysis by filing period
Read the full thesis on Biocon
Biocon's Strategic Entry into the Global GLP-1 Market: A Deep Dive into Vertically Integrated Weight Loss Solutions
18 May 2026Biocon and the GLP-1 Opportunity: Scaling Manufacturing for the Global Weight Loss Market
17 May 2026Biocon and the GLP-1 Opportunity: Scaling Manufacturing for the Global Weight Loss Market
11 May 2026AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.